S&P 500   3,970.90 (+1.78%)
DOW   31,900.27 (+2.04%)
QQQ   292.20 (+1.22%)
AAPL   142.33 (+3.45%)
MSFT   259.79 (+2.86%)
FB   194.74 (+0.62%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   668.89 (+0.75%)
NVDA   167.00 (+0.04%)
BABA   86.65 (-0.16%)
NIO   15.71 (-4.44%)
AMD   94.10 (+0.64%)
CGC   5.15 (-6.70%)
MU   69.37 (+0.68%)
T   20.85 (+2.21%)
GE   75.97 (+0.96%)
F   12.83 (+2.64%)
DIS   104.91 (+2.43%)
AMC   11.59 (-3.66%)
PFE   53.04 (+1.09%)
PYPL   81.10 (+0.70%)
NFLX   185.17 (-0.63%)
S&P 500   3,970.90 (+1.78%)
DOW   31,900.27 (+2.04%)
QQQ   292.20 (+1.22%)
AAPL   142.33 (+3.45%)
MSFT   259.79 (+2.86%)
FB   194.74 (+0.62%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   668.89 (+0.75%)
NVDA   167.00 (+0.04%)
BABA   86.65 (-0.16%)
NIO   15.71 (-4.44%)
AMD   94.10 (+0.64%)
CGC   5.15 (-6.70%)
MU   69.37 (+0.68%)
T   20.85 (+2.21%)
GE   75.97 (+0.96%)
F   12.83 (+2.64%)
DIS   104.91 (+2.43%)
AMC   11.59 (-3.66%)
PFE   53.04 (+1.09%)
PYPL   81.10 (+0.70%)
NFLX   185.17 (-0.63%)
S&P 500   3,970.90 (+1.78%)
DOW   31,900.27 (+2.04%)
QQQ   292.20 (+1.22%)
AAPL   142.33 (+3.45%)
MSFT   259.79 (+2.86%)
FB   194.74 (+0.62%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   668.89 (+0.75%)
NVDA   167.00 (+0.04%)
BABA   86.65 (-0.16%)
NIO   15.71 (-4.44%)
AMD   94.10 (+0.64%)
CGC   5.15 (-6.70%)
MU   69.37 (+0.68%)
T   20.85 (+2.21%)
GE   75.97 (+0.96%)
F   12.83 (+2.64%)
DIS   104.91 (+2.43%)
AMC   11.59 (-3.66%)
PFE   53.04 (+1.09%)
PYPL   81.10 (+0.70%)
NFLX   185.17 (-0.63%)
S&P 500   3,970.90 (+1.78%)
DOW   31,900.27 (+2.04%)
QQQ   292.20 (+1.22%)
AAPL   142.33 (+3.45%)
MSFT   259.79 (+2.86%)
FB   194.74 (+0.62%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   668.89 (+0.75%)
NVDA   167.00 (+0.04%)
BABA   86.65 (-0.16%)
NIO   15.71 (-4.44%)
AMD   94.10 (+0.64%)
CGC   5.15 (-6.70%)
MU   69.37 (+0.68%)
T   20.85 (+2.21%)
GE   75.97 (+0.96%)
F   12.83 (+2.64%)
DIS   104.91 (+2.43%)
AMC   11.59 (-3.66%)
PFE   53.04 (+1.09%)
PYPL   81.10 (+0.70%)
NFLX   185.17 (-0.63%)
LON:IMM

ImmuPharma (IMM) Share Forecast, Price & News

GBX 5.95
+0.10 (+1.71%)
(As of 05/23/2022 04:17 PM ET)
Add
Compare
Today's Range
5.94
▼
6.34
50-Day Range
5.39
▼
8.04
52-Week Range
4.80
▼
10.90
Volume
486,311 shs
Average Volume
1.27 million shs
Market Capitalization
£16.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

ImmuPharma logo

About ImmuPharma

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, metabolism, anti-infectives, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Headlines

May 21, 2022 | americanbankingnews.com
ImmuPharma (LON:IMM) Stock Price Crosses Below 200 Day Moving Average of $6.41
May 13, 2022 | americanbankingnews.com
ImmuPharma (LON:IMM) Shares Pass Below Two Hundred Day Moving Average of $6.45
May 9, 2022 | lse.co.uk
Mpac Group Plc News Headlines. MPAC Share News. Financial News Articles for Mpac Group Plc Ord 25P updated throughout the day. - London South East
May 6, 2022 | morningstar.co.uk
TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well - Morningstar
May 6, 2022 | lse.co.uk
TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well | Financial News - London South East
May 5, 2022 | marketwatch.com
ImmuPharma Shares Rise on Lupus Phase 3 Studies Preparations - MarketWatch
May 5, 2022 | americanbankingnews.com
ImmuPharma (LON:IMM) Stock Passes Below 200-Day Moving Average of $6.49
May 4, 2022 | proactiveinvestors.com
ImmuPharma says phase III trial preparations are underway - Proactive Investors USA
April 17, 2022 | proactiveinvestors.com
Proactive health highlights: Poolbeg, SourceBio, Immupharma and more - Proactive Investors USA
April 13, 2022 | proactiveinvestors.com
Proactive news headlines: Immupharma, Open Orphan, Union Jack, and more - Proactive Investors USA
April 13, 2022 | proactiveinvestors.com
FTSE 100 rises despite more grim news on inflation with mining giants leading the gains - Proactive Investors USA
April 13, 2022 | morningstar.co.uk
AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract - Morningstar
April 13, 2022 | proactiveinvestors.com
ImmuPharma drug clears a significant hurdle - Proactive Investors USA
See More Headlines

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:IMM
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.immupharma.org
Phone
+44-20-71524080
Fax
N/A
Employees
18
Year Founded
N/A

Sales & Book Value

Annual Sales
£87.99 thousand
Price / Sales
192.71
Cash Flow
GBX 1.60 per share
Price / Cash Flow
3.73
Book Value
GBX 2.10 per share
Price / Book
2.83

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
12.36
Current Ratio
2.68
Quick Ratio
2.59

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
284,985,000
Free Float
N/A
Market Cap
£16.96 million
Optionable
Not Optionable

Company Calendar

Last Earnings
9/30/2020
Today
5/23/2022
Next Earnings (Estimated)
5/23/2022

MarketRank™

Overall MarketRank™

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













ImmuPharma (LON:IMM) Frequently Asked Questions

When is ImmuPharma's next earnings date?

ImmuPharma is scheduled to release its next quarterly earnings announcement on Monday, May 23rd 2022.
View our earnings forecast for ImmuPharma.

How were ImmuPharma's earnings last quarter?

ImmuPharma plc (LON:IMM) announced its quarterly earnings data on Wednesday, September, 30th. The company reported ($1.69) earnings per share (EPS) for the quarter.
View ImmuPharma's earnings history.

Who are ImmuPharma's key executives?
ImmuPharma's management team includes the following people:
  • Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA, Acting Chairman & CEO (Age 65, Pay $260k)
  • Ms. Ewa Flynn M.A., Chief Financial Officer & Company Sec.
  • Dr. Timothy Gary Franklin M.B.A., Ph.D., COO & Director
  • Ms. Lisa Baderoon, Head of Investor Relations & Non Exec. Director
  • Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.
What other stocks do shareholders of ImmuPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Mining (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA).

What is ImmuPharma's stock symbol?

ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

How do I buy shares of ImmuPharma?

Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ImmuPharma's stock price today?

One share of IMM stock can currently be purchased for approximately GBX 5.95.

How much money does ImmuPharma make?

ImmuPharma has a market capitalization of £16.96 million and generates £87.99 thousand in revenue each year.

How many employees does ImmuPharma have?

ImmuPharma employs 18 workers across the globe.

What is ImmuPharma's official website?

The official website for ImmuPharma is www.immupharma.org.

How can I contact ImmuPharma?

ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.